Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA9 | P38646 | 4/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28250850 | 0.82 | NT5E (0.47) | HSPA9NT5ECHRM5BACE1CTSD | |
| SCHEMBL3819871 | 0.81 | MAPT (0.43) | MPITDP1 | |
| SCHEMBL9750166 | 0.77 | MPI (0.40) | HSPA9MPITDP1SLC6A4TMEM97 | |
| SCHEMBL9750257 | 0.77 | GRIA2 (0.42) | MPITDP1 | |
| SCHEMBL9750440 | 0.77 | GRIA2 (0.42) | MPITDP1 | |
| SCHEMBL9734981 | 0.75 | PDK2 (0.39) | MPITDP1SIGMAR1KCNH2 | |
| SCHEMBL4602881 | 0.74 | MPI (0.43) | NT5EMPITDP1 | |
| SCHEMBL3819527 | 0.74 | NQO2 (0.40) | MPITDP1 | |
| SCHEMBL10881205 | 0.74 | PDK2 (0.39) | MPITDP1 | |
| SCHEMBL9750113 | 0.73 | GRIA2 (0.45) | MPITDP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891038-B2 | Photochromic spiro(indoline)naphthoxazines | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-05-10 | — | — | US | disclosed |
| US-20030114669-A1 | Photochromic spiro(indoline)naphthoxazines | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2003-06-19 | — | — | US | disclosed |
| EP-1272494-A2 | PHOTOCHROMIC SPIRO(INDOLINE)NAPHTHOXAZINES | Yeda Research and Development Co. Ltd. (IL) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077112-A2 | PHOTOCHROMIC SPIRO(INDOLINE)NAPHTHOXAZINES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114669-A1 | Photochromic spiro(indoline)naphthoxazines | NPM1, CRY2, INMT | HSPA9 4795/4885NT5E 3056/4885MPI 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.